In the BioHarmony Drug Report Database
Folotyn (pralatrexate) is a small molecule pharmaceutical. Pralatrexate was first approved as Folotyn on 2009-09-24. It is used to treat t-cell lymphoma peripheral in the USA. The pharmaceutical is active against dihydrofolate reductase. Folotyn’s patents are valid until 2025-05-31 (FDA).
Image (chem structure or protein)